{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:06:50Z","timestamp":1788527210991,"version":"build-2803163510"},"reference-count":35,"publisher":"SLACK, Inc.","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Ann"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:p>The landscape of pediatric hematopoietic cell transplantation for nonmalignant disorders has evolved through disease-adapted conditioning, pharmacokinetic-guided dosing, expanded donor options, and gene therapy (GT). These advances have transformed curative strategies for children with select inborn errors of immunity, hemophagocytic lymphohistiocytosis, hemoglobinopathies, bone marrow failure syndromes, and select metabolic disorders. Early diagnosis, especially newborn screening for severe combined immunodeficiency, enables timely intervention, with contemporary series reporting more than 90% survival in select early-treated infants. Similarly, modern matched related donor transplantation for pediatric severe aplastic anemia approaches 98% 3-year survival. Fludarabine-based platforms combined with busulfan, melphalan, or treosulfan support durable engraftment with reduced toxicity, while matched unrelated, haploidentical, and cord blood donors expand access. GT now offers a parallel curative platform for select sickle cell disease, transfusion-dependent beta-thalassemia, and immunodeficiencies. For pediatricians, early referral before irreversible complications is critical. This review proposes a five-axis framework to guide referral, treatment selection, and survivorship planning.<\/jats:p>","DOI":"10.3928\/19382359-20260628-01","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:53:25Z","timestamp":1788486805000},"source":"Crossref","is-referenced-by-count":1,"title":["Pediatric Nonmalignant Hematopoietic Cell Transplantation in the Era of Precision Conditioning and Gene Therapy"],"prefix":"10.3928","volume":"55","author":[{"given":"Eman M.","family":"Elsabbagh","sequence":"first","affiliation":[{"name":"Clinical Research Program, Duke University School of Medicine, Durham, North Carolina and CITADEL Lab, Computational Immunology &amp; Transplant AI Data Engineering Lab;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Shawky","sequence":"additional","affiliation":[{"name":"School of Medicine, Mansoura University, Mansoura, Egypt;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Dvorak","sequence":"additional","affiliation":[{"name":"Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00731-6"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401177"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.05.014"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01378-8"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-828277"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001748"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.03.008"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.12.1010"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.11.009"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211013985"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.09.024"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30114-4"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013275"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.12.007"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00045-9"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014836"},{"key":"e_1_3_1_18_2","unstructured":"US Food and Drug Administration. FDA approves treosulfan and fludarabine as a preparative regimen for allo-HCT in adult and pediatric patients 1 year or older with AML or MDS. Published January 21 2025. Accessed August 20 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-treosulfan-fludarabine-preparative-regimen-allohsct-adult-and-pediatric-patients-aml-or"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.02.002"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024038"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-455238"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-140830"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031054"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309673"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027675"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30021-3"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0735-5"},{"key":"e_1_3_1_28_2","unstructured":"US Food and Drug Administration. FDA approves first gene therapy treatment for Wiskott-Aldrich Syndrome. Published December 9 2025. Accessed August 20 2026. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-treatment-wiskott-aldrich-syndrome"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1700554"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30374-9"},{"key":"e_1_3_1_31_2","unstructured":"US Food and Drug Administration. SKYSONA (elivaldogene autotemcel) package insert. Updated July 2025. Accessed August 20 2026. https:\/\/www.fda.gov\/media\/161640\/download"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106596"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.309"},{"key":"e_1_3_1_34_2","unstructured":"US Food and Drug Administration. LYFGENIA summary basis for regulatory action. Published December 8 2023. Accessed August 20 2026. https:\/\/www.fda.gov\/vaccines-blood-biologics\/lyfgenia"},{"key":"e_1_3_1_35_2","unstructured":"Congressional Budget Office. How increased use of gene therapy treatment for sickle cell disease could affect the federal budget. December 31 2024. Accessed August 13 2026. https:\/\/www.cbo.gov\/publication\/60775"},{"key":"e_1_3_1_36_2","unstructured":"Orchard Therapeutics. Orchard Therapeutics outlines U.S. launch plans for Lenmeldy\u2122 (atidarsagene autotemcel) the only approved therapy for children with early-onset meta-chromatic leukodystrophy. Published March 20 2024. Accessed August 20 2026. https:\/\/ir.orchard-tx.com\/news-releases\/news-release-details\/orchard-therapeutics-outlines-us-launch-plans-lenmeldytm\/"}],"container-title":["Pediatric Annals"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:53:30Z","timestamp":1788486810000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/19382359-20260628-01"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"alternative-id":["10.3928\/19382359-20260628-01"],"URL":"https:\/\/doi.org\/10.3928\/19382359-20260628-01","relation":{},"ISSN":["0090-4481","1938-2359"],"issn-type":[{"value":"0090-4481","type":"print"},{"value":"1938-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}